Stockscreener 앱 받기
24.02
9.80%
-2.61
시간 외 거래:
24.02
전일 마감가:
$26.63
열려 있는:
$25
하루 거래량:
2.71M
Relative Volume:
3.29
시가총액:
$1.73B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-10.87
EPS:
-2.21
순현금흐름:
$-106.82M
1주 성능:
-11.53%
1개월 성능:
-19.75%
6개월 성능:
-45.66%
1년 성능:
-44.29%
1일 변동 폭
$22.34
$25.00
1주일 범위
$22.34
$27.68
52주 변동 폭
$22.34
$51.61
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
24.02 | 1.73B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com India
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - Simply Wall St
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
(VERA) On The My Stocks Page - news.stocktradersdaily.com
What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World
Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating - Marketscreener.com
Guggenheim raises Vera Therapeutics stock target to $61 - Investing.com India
Can Vera Therapeutics Reveal New Immunology Pipeline Updates at Upcoming TD Cowen Conference? - StockTitan
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook - TipRanks
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing By Investing.com - Investing.com South Africa
Vera Therapeutics 2024 Loss Widens -February 26, 2025 at 08:53 am EST - Marketscreener.com
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing - Investing.com India
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M - Marketscreener.com
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss - Marketscreener.com
Vera Therapeutics, Inc. Reports 2024 Business Highlights and Financial Results; On Track for Phase 3 ORIGIN Trial Results and FDA Submission for Atacicept in IgA Nephropathy - Nasdaq
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025 - StockTitan
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
(VERA) Trading Advice - Stock Traders Daily
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily
Cantor Fitzgerald maintains Overweight on Vera Therapeutics stock By Investing.com - Investing.com Nigeria
Evercore ISI maintains Vera Therapeutics stock with $75 target By Investing.com - Investing.com Canada
Evercore ISI maintains Vera Therapeutics stock with $75 target - Investing.com
Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo - MSN
Vera Therapeutics stock drops amid rival drug update - MSN
Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year LowWhat's Next? - MarketBeat
Vera Therapeutics stock drops amid rival drug update By Investing.com - Investing.com Australia
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):